Scientists at Trinity College Dublin have unveiled a technique that amplifies the body’s own immune cells to fight drug‑resistant pathogens.. Led by immunologist Dr. Dearbhla Murphy, the team used interferon‑gamma to prime macrophages, achieving faster and stronger microbial killing in laboratory experiments. The approach could one day complement or replace anntibiotics for infections that no longer respond to drugs.

Dr. Dearbhla Murphy’s interferon‑gamma macrophage boost

According to the research report, Dr. Murphy’s group exposed macrophages—the immune system’s first‑line phagocytes—to interferon‑gamma, a signalling molecule naturally released during infections. The treated cells displayed a markedly accelerated response, engulfing and destroying bacteria, fungi and viruses more efficiently than untreated controls. The scientists cite earlier vaccine studies that showed interferon‑gamma‑driven gene activation reduced mortality from unrelated infections, providing a conceptual bridge to their current work.

Fast‑track results against fungi and viruses in lab tests

The laboratory data revealed that supercharged macrophages killed a range of drug‑resistant microbes, including Candida species and multi‑drug‑resistant Staphylococcus aureus, within hours. In viral assays, the enhanced cells limited replication of influenza‑like viruses, suggesting a broad‑spectrum potential. as the source notes, the method could theoretically target “fungi, viruses, and other infections severe enough to be resistant to many medications.”

Potential safety concerns from interferon‑gamma overstimulation

Experts warn that amplifying innate immunity carries risks. Interferon‑gamma therapy in humans has been linked to flu‑like symptoms, muscle aches, headaches and fatigue, and excessive inflammation could damage healthy tissue . The report cautions that “amping up immune activity too much could cause side effects such as excessive inflammation or tissue damage,” and that autoimmune flare‑ups remain a theoretical danger.

What clinical translation timeline remains unknown

While the findings are promising, the article emphasizes that further research is needed before any clinical rollout.. it is still unclear whether a drug‑like formulation of interferon‑gamma can be safely administered, or how long it would take to move from bench to bedside. as of now, no human trials have been announced, leaving the timeline for real‑world impact uncertain.